Pharmafile Logo
Pharmafocus logo
Advanced Search

MS

Showing 15 posts of 91 posts found.

robina-weermeijer-ihfopazzjhm-unsplash_5

FDA approves Sandoz’s Tyruko biosimilar to treat relapsing forms of MS

August 25, 2023
Medical Communications FDA, MS, Neurology, Sandoz

Novartis’ Sandoz has announced that the US Food and Drug Administration (FDA) has approved its biosimilar Tyruko (natalizumab-sztn), developed by …

News
needle-1291170_960_720

Genentech shares results from phase 3 trial for MS treatment

July 13, 2023
Research and Development Genentech, MS, Neurology, Ocrevus, clinical trial

Genentech has announced positive results from its phase 3 OCARINA II trial which assessed Ocrevus (ocrelizumab) as a twice-a-year, ten-minute …

News
dw-anzcxqaqavhl

FDA approves new IM administration route for Biogen’s MS drug Plegridy

February 2, 2021
Manufacturing and Production Biogen, MS

The FDA has approved a new intramuscular (IM) injection route of administration for Biogen’s Plegridy (peginterferon beta-1a) for the treatment …

News
download_1

Roche to start new trials of Ocrevus to defend multiple sclerosis franchise

September 9, 2020
Research and Development MS, MS drug, Roche

Roche is to begin expanding trials of Ocrevus in multiple sclerosis (MS) patients to defend its MS franchise from its …

News
6127242068_23c80ef94f_b

Sanofi to buy Principia Biopharma for $3.4 billion

August 17, 2020
Sales and Marketing MS, Sanofi

Sanofi is set to buy California based Principia Biopharma in a deal that is worth $3.4 billion. This deal means …

News

Novartis releases results of MS drug trials weeks ahead of FDA verdict

May 28, 2020
Business Services MS, Novartis

Novartis has revealed clinical trial data from testing its anti-CD20 leukameia drug Arzerra (ofatumumab) in patients with multiple sclerosis (MS). …

News
mrt_big

FDA approves MS drug for human trials

January 27, 2020
Sales and Marketing MS, MS symptoms, MS treatment, Neuro, neurology

A drug that can make it easier to diagnose Multiple Sclerosis (MS) has been approved for its first human trials …

News
6127243966_e9189f1099_b

Multiple sclerosis market to be worth $32.9bn in 2028

December 11, 2019
Research and Development Big Pharma, MS, MS treatement, multiple sclerosis, pharma

The multiple sclerosis (MS) market is expected to see a growth in sales, and increase from $19.8 billion in 2018 …

News

MS drug boosts effectiveness of cancer therapy in treating glioblastoma, study shows

August 9, 2019
Medical Communications MS, brain cancer, glioblastoma, oncology, pharma

The multiple sclerosis (MS) drug teriflunomide boosts the effectiveness of cancer drugs in treating glioblastoma, according to researchers from UC, …

News
30805878966_19824f12fd_z

MRI scans can help predict MS patient’s long term prognosis, 15 year study shows

July 25, 2019
Research and Development CIS, MRI scans, MS, Prognosis, diagnosis, multiple sclerosis, pharma

MRI scans can predict MS patient’s long term prognosis when they are first diagnosed, according to new research. In a …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

April 18, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, Genentech, Gilead, HIV, MS, Novartis, kidney disease, pharma

This week was a good one for clinical trials and a bad one for employees after both Gilead and GSK …

News
novartis_side_building

Novartis’ new MS drug to cost $88,000 a year

March 27, 2019
Research and Development, Sales and Marketing FDA, MS, Novartis, Novartis pharmaceuticals, multiple sclerosis

Paul Hudson, the CEO of Swiss firm Novartis Pharmaceuticals has said the company’s newly approved multiple sclerosis (MS) drug will …

News
psm_v46_d168_mesial_view_of_the_human_brain

Drug slows brain shrinkage associated with progressive multiple sclerosis, study shows

August 30, 2018
Research and Development MS, brain, ibudilast, neuroscience, research

The multiple sclerosis drug ibudilast, slowed brain shrinkages in patients with progressive MS, a study published in the New England …

News
roche__tree

Roche’s Ocrevus cleared for NHS use in relapsing-remitting MS

June 22, 2018
Medical Communications, Sales and Marketing MS, NICE, UK, multiple sclerosis, pharma

Roche and multiple sclerosis (MS) patients across England and Wales are celebrating the news that healthcare watchdog NICE has recommended …

News

NICE recommends Novartis’ Extavia for MS, but knocks back a raft of other beta interferons

December 20, 2017
Research and Development, Sales and Marketing Extavia, MS, NICE, Novartis, beta interferon, multiple sclerosis

NICE has revealed that it has passed draft guidance that recommends Novartis’ Extavia (interferon beta 1b) for the treatment of …

News

Latest content

FDA approves Novartis’ Fabhalta for PNH treatment

December 6, 2023

Teva Pharmaceuticals shares phase 3 data for Ajovy as migraine treatment

December 6, 2023

British Medical Journal publishes letter calling on government to reduce rate of antidepressant prescribing

December 5, 2023

Genentech shares positive results from phase 3 trial for breast cancer treatment

December 5, 2023

Dr Stefano Gulià appointed as chief scientific officer of Kling Bio

December 5, 2023